AzTrials
AzTrials

Heart FailureWeRoaM:NCT06969560

WeRoaM: Wearable Remote Monitoring in Heart Failure

An observational study of Heart Failure, run by University of Alberta at 4 sites in Canada.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Remote physiologic monitoring (RPM) of heart failure (HF) patients with a virtual platform is well established in adult care. However, this technology remains untested in pediatrics and care continues to rely on a hospital-based model which presents challenges in providing equitable access to care for those with lower… Read more about this study

Who is it for?
Ages 8 to 18 years
Conditions the study is for
Heart Failure
What is being tested?
Remote Physiologic Monitoring (RPM)
Type of treatment
Medical device
How many people
100 participants
Where
4 sitesCanada
Study dates
24 Feb 2025to 31 Dec 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 8 to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Study population: This study will enroll 100 paediatric outpatients (8 to 18 years old) with diagnosis of cardiomyopathy (with systolic or diastolic dysfunction), subjects with congenital heart disease with biventricular or univentricular physiology plus systemic ventricular dysfunction from 4 tertiary heart failure care centres.

Who may be able to join

  • Patients from 8-18 years of age who are outpatients at time of study enrollment.
  • Patients with a chest size of at least 69.85 cm in perimeter/circumference (as measured under the pectoral muscles)
  • Patients at-risk for heart failure and with American Heart Association (AHA) Stage B-D Heart Failure will be included in this study irrespective of heart failure medication use.
  • HF etiologies include: congenital cardiac malformation with systemic ventricular systolic dysfunction, idiopathic cardiomyopathy, familial/inherited and/or genetic cardiomyopathy, history of myocarditis with persistent ventricular dysfunction, neuromuscular disorder, inborn error of metabolism, mitochondrial disorder, acquired (chemotherapy, iatrogenic, infection, rheumatic, or nutritional), ischemic (e.g., Kawasaki disease and post-operative HF), and left ventricular non-compaction, restrictive cardiomyopathy and HCM with systolic or diastolic dysfunction.

Who cannot join

  • Patients within 3 months of a surgery.
  • Patients supported by ventricular assist device at study onset.
  • Inability to use technology due to physical or cognitive impairment in the patient or caregiver.
  • Non-English speaking.
  • Patients who have an implantable cardiac defibrillator or pacemaker
  • Patients whose chest size is too large or small to fit available sizes of the Skiin device.

Trial locations and contacts

4 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Jennifer L Conway, MD, MSc contact

780-407-4848

jennifer.conway2@ahs.ca

Tara L Pidborochynski, MSc contact

780-407-1899

tara.pidborochynski@ahs.ca

Canada4 sites, 4 recruiting
  • Stollery Children's Hospital

    Edmonton, Alberta, T6G 2B7

    Jennifer L Conway, MD, MSc, 780-407-4848, jennifer.conway2@ahs.ca

    Tara L Pidborochynski, MSc, 780-407-1899, tara.pidborochynski@ahs.ca

    Recruiting
  • CHU Sainte-Justine

    Montreal, Quebec, QC H3T

    Nassiba Alami Laroussi, MD, nassiba.alami.med@ssss.gouv.qc

    Frederique Provencher, frederique.provencher.hsj@ssss.gouv.qc.ca

    Not yet recruiting
  • The Hospital for Sick Children

    Toronto, Ontario, M5G 1E8

    Aamir Jeewa, MD, 416-813-6140, aamir.jeewa@sickkids.ca

    Diana Balmer-Minnes, diana.balmer-minnes@sickkids.ca

    Not yet recruiting
  • BC Children's Hospital

    Vancouver, British Columbia, V6H 3N1

    Kathryn Armstrong, MD, kathryn.armstrong@cw.bc.ca

    Melanie Kardel, Melanie.Kardel@bcchr.ca

    Not yet recruiting

Other trials in Canada

About this study

Official title: There's No Place Like Home…Feasibility of Remote Physiological Monitoring in Childhood Heart Failure

Remote physiologic monitoring (RPM) of heart failure (HF) patients with a virtual platform is well established in adult care. However, this technology remains untested in pediatrics and care continues to rely on a hospital-based model which presents challenges in providing equitable access to care for those with lower socio-economic status or living remotely. Telemonitoring technology tailored for children with machine-based algorithms to predict deterioration is needed to facilitate the equitable provision of safe, home-based care, especially in vulnerable populations.

This study will enroll 100 pediatric outpatients with or at risk of deteriorating HF from 4 tertiary pediatric heart failure care centres in Canada. We will use a wearable Bluetooth enabled textile (Skiin device), developed by Myant Inc (Toronto, ON), that can monitor heart rate, heart rhythm, respiratory rate and activity, together with additional home-based monitoring of blood pressure (BP), oxygen saturations and weight. The smart textile will be paired to an RPM platform, SphygmoTM (mmHG Inc).

The goal of this project is to assess the feasibility and acceptability of RPM in pediatrics and validate a RPM-based risk prediction model for pediatric HF patients.

Read the detailed description

Remote physiologic monitoring (RPM) refers to utilizing non-invasive medical devices to obtain physiologic data, such as pulse oximetry, blood pressure, weight, and electrocardiography at home. Recent advances in RPM have facilitated improved home-based care, reduced hospitalizations, and improved quality of life in adult heart failure populations. Additionally, the integration of multiple physiologic variables acquired through remote physiologic monitoring into machine learning algorithms has been shown to predict hospitalization for heart failure. Previous paediatric studies have demonstrated the utility of incorporating multiple physiologic variables into risk prediction algorithms for cardiac events. This is particularly important in heart failure cohorts where limits of acceptability are often nuanced and patient specific. The use of multiple physiologic parameters creates a more comprehensive insight into the complex pathophysiologic changes in heart failure.

However, the use of RPM devices in children remains limited due to a lack of validated devices and uncertainty about the acceptability and uptake of such interventions. This is partly due to challenges developing devices that can be easily applied, and digital platforms suited to the wider range and variability in body sizes and physiologic parameters. Thus, care of children with heart failure continues to rely on hospital-based models, where tertiary heart failure centers serve large geographically and socio-economically diverse populations. A validated paediatric virtual home monitoring system using RPM to predict clinical deterioration could safely facilitate earlier discharge, reduce the need for outpatient hospital visits, and potentially improve outcomes while minimizing family social disruption and school absence.

The overarching goal of this project is to assess the feasibility of RPM in paediatrics and validate a RPM based risk prediction model for paediatric patients with or at-risk of heart failure, with a view to facilitating safe home-based care across geographically and socially diverse urban, rural, and remote communities. To achieve this goal, this study proposes to utilize a wearable Bluetooth enabled textile (Skiin Device) that can monitor heart rate and rhythm, respiratory rate and activity, together with additional home-based monitoring of blood pressure, oxygen saturations and weight. The textile, developed by Myant (Toronto, ON) has completed pilot testing at SickKids to assess its validity in an outpatient setting (NCT04305340). The Skiin textile will be paired to its software solution, the Myant Health Platform (MHP), which comprises the Skiin Connected Life App (phone application), the Myant Back End (cloud storage of data) and the Myant Virtual Clinical Portal (internet browser visualization of data collected). The Skiin Connected Life App will be used for collection of ECG, heart rate, body temperature, and physical activity throughout the day, and can generate the following average metric for each night when the device is used: resting heart rate, respiratory rate, resting heart rate variability, sleep duration, body temperature.

The MHP will be paired with another RPM platform, SphygmoTM (mmHG Inc). The Sphygmo™ platform consists of a smartphone App (Android, iOS), which can be linked with Bluetooth-compatible devices for automated uploading of measurements to a clinician portal. This platform, originally developed for adults, has the ability to connect with blood pressure, heart rate, weight, and oxygen saturation devices. This platform will be used for collection of additional physiologic data as above and is currently under study at Stollery Children's Hospital. The two systems will have a single-sign on feature allowing their integrated use by the patient, their families, and the research team. We will leverage descriptive and predictive analytics to augment clinician monitoring by defining trajectories and longitudinally predicting risk of key adverse outcomes.

Study Objectives Primary Objectives

  1. To investigate the feasibility of a remote physiological monitor using a textile smart garment (Skiin devices) using the Skiin Connected Life App along with additional standard home monitoring tools (BP monitor, weigh scales) that are paired with a Bluetooth enabled app (SphygmoTM)
  2. To test the acceptability of a remote physiological monitor using a textile smart garment (Skiin devices) along with the acceptability of a Bluetooth enabled app (SphygmoTM)

Secondary Objectives

  1. To leverage analytical methods to develop descriptive and predictive tools using RPM that augment detection of clinical deterioration in pediatric patients as measured by admission, adverse cardiac events and patient reported outcomes within 6-months post intervention.

Study Duration: Patients will be recruited over a 2-year period.

Conditions
Heart Failure
Being tested
Remote Physiologic Monitoring (RPM)
Keywords
remote physiologic monitoring, heart failure, at-risk, telemonitoring technology, pediatric
Medical subject headings
Heart Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Remote Physiologic Monitoring (RPM)Device

    The intervention consists of a remote physiologic monitoring (RPM) program which makes use of a wearable Skiin chest band and ECG device, a blood pressure monitor, a pulse oximeter, and a weight scale; the RPM program will occur for 12 weeks Participants will wear the Skiin device continuously for the first 48-hours and then for a 12-hour span each day following that. Participants will measure their blood pressure, oxygen saturation, and weight once a day for the full 12 weeks.

Study groups in NCT06969560
Study groupRoleWhat they receive
paediatric outpatients (8 to 18 years old) with diagnosis of cardiomyopathyThis study will enroll 100 paediatric outpatients (8 to 18 years old) with diagnosis of cardiomyopathy (with systolic or diastolic dysfunction), subjects with congenital heart disease with biventricular or univentricular physiology plus systemic ventricular dysfunction from 4 tertiary heart failure care centres. Patients will participate in a remote physiologic monitoring program using bluetooth enabled devices for 12 weeks. Devices as part of the study intervention include: Skiin chest band and ECG device; blood pressure monitor; pulse oximeter; weight scale.
Receives: Device: Remote Physiologic Monitoring (RPM)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Feasibility of Remote Physiologic Monitoring (RPM) Program- Recruitment

    Feasibility will be assessed by recruitment rates (the number of participants recruited

    Measured: 2 years

  2. Feasibility of Remote Physiologic Monitoring (RPM) Program- Retention

    Feasibility will be assessed by retention rate (the number of participants who complete measures at baseline and at follow up post intervention)

    Measured: 2 years

  3. Feasibility of Remote Physiologic Monitoring (RPM) Program- Access

    Feasibility will be assessed by the percentage of people with access to Wi-Fi and smart device

    Measured: 2 years

  4. Acceptability of Remote Physiologic Monitoring (RPM) Program

    Acceptability will be assessed by compliance defined as >80% of the physiologic monitoring requested has been captured twice daily for a period of 12 weeks; completion of the Medtech 20 questionnaire will also inform on acceptability.

    Measured: 2 years

Secondary outcomes (1)
  1. Composite End-Point Assessing Remote Physiologic Monitoring (RPM) Program

    For the secondary outcome we will use a composite end-point. Given the low prevalence and rarity of events such as death or transplant from chronic heart failure in paediatrics, there is limited potential for large outcome trials. As a result, we will use a composite end-point designed for the PANORAMA-HF study and based on Packer's composite score which has been extensively used in adult heart failure studies.

    Patients will be ranked within 5 categories from worst to best based on heart failure events such as death, transplant listing, need for mechanical circulatory supports, as well as progression of heart failure symptoms by NYHA or Ross Class and patient reported outcomes as assessed by the PedsQL and PGIS. Patients who experience a clinical event during follow up will be classified into category 1 and 2. Patients without a clinical event during follow up will be divided into 3, 4 and 5 based on change from baseline symptoms and functional capacity.

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 May 2025
  2. Study start24 Feb 2025
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06969560
Sponsor's protocol ID
Pro00126084
Acronym
WeRoaM:
Status last verified
May 2026
First submitted
22 Apr 2025
Last updated
11 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: To protect participant privacy and confidentiality, no IPD will be shared. Only group trends will be reported.

Questions about this trial

What is this clinical trial studying?

An observational study of Heart Failure, run by University of Alberta at 4 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 11 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Jennifer L Conway, MD, MSc (780-407-4848, jennifer.conway2@ahs.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Feasibility of Remote Physiologic Monitoring (RPM) Program- Recruitment (time frame: 2 years). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in